Table 4.
Comparison studies between RRP and RRP
| Author, years [ref] | Krambeck, 2009 [16] | Barocas, 2010 [17] | Park, 2014 [8] | Hu, 2014 [5] | Alemozaffar, 2015 [6] | Yaxley, 2016 [4] | Present study | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procedure | RRP | RARP | RRP | RARP | RRP | RARP | RRP | RARP | RRP | RARP | RRP | RARP | RRP | RARP |
| No. of patients | 588 | 294 | 491 | 1413 | 277 | 730 | 5524 | 5524 | 621 | 282 | 163 | 163 | 490 | 418 |
| Age | 61 | 61 | 62 | 61 | 66.8 | 64.2 | 69 | 69 | 67.2 | 65.4 | 60.4 | 59.6 | 67 | 67 |
| PSA (median, range) | 5.0 (0.6–39.7) | 4.9 (0.5–33.5) | 5.8 (4.6–8.4) | 5.4 (4.3–7.4) | 10.3 (−) | 9.2 (−) | - | - | 5.6 (−) | 5.0 (−) | 7.57 (4–7) | 7.41 (4–10) | 7.9 (1.3–77) | 7.6 (1.4–71) |
| GS | ||||||||||||||
| 6 or less | 391 (66.5) | 192 (65.5) | 221 (45.3) | 723 (51.5) | 54 (19.5) | 167 (22.9) | 1958 (35.4) | 1748 (31.6) | - (62.7) | - (53) | 20 (15) | 23 (18) | 148 (30) | 23 (5) |
| 7 | 167 (28.4) | 87 (29.7) | 213 (43.6) | 588 (41.8) | 159 (57.4) | 458 (62.7) | 2866 (51.9) | 3224 (58.4) | - (28.9) | - (37) | 92 (68) | 87 (67) | 295 (60) | 288 (69) |
| 8–10 | 30 (5.1) | 14 (4.8) | 54 (11.1) | 94 (6.7) | 64 (23.1) | 105 (14.4) | 700 (12.7) | 552 (10.0) | - (8.4) | - (10) | 14 (17) | 20 (15) | 47 (9.7) | 107 (26) |
| PSM (%) | ||||||||||||||
| Total | 100 (17) | 46 (15.6) | 148 (30.1) | 281 (19.9) | 58 (20.9) | 170 (23.3) | 1010 (18.3) | 752 (13.6) | - (23.1) | - (24.6) | 15 (10) | 23 (15) | 213 (44) | 89 (21) |
| pT2 | - | - | - | - | 7.8 | 11.2 | 3.8 | 2.5 | - | - | 2 | 3 | 33 | 10 |
| pT3 | - | - | - | - | 36.5 | 44.7 | 18.5 | 13.7 | - | - | 12 | 11 | 76 | 53 |
| pT4 | - | - | - | - | - | - | - | - | 40 | - | ||||
| Sites of PSM | ||||||||||||||
| Base | 10 (10) | 4 (8.7) | - | - | 2 (3.4) | 12 (7.1) | - | - | - | - | 33 (6.7) | 32 (7.7) | ||
| Lateral lobe | 49 (49) | 27 (59) | - | - | 16 (27.6) | 48 (28.2) | - | - | - | - | 62 (13) | 24 (5.7) | ||
| Apex | 56 (56) | 13 (28) | - | - | 22 (37.9) | 58 (34.1) | - | - | - | - | 136 (28) | 33 (7.8) | ||
| Anterior | 5 (5) | 1 (2) | - | - | - | - | - | - | - | - | 5 (1) | 5 (1) | ||
| Posterior | - | - | - | - | - | - | - | - | - | - | 3 (0.6) | 1 (0.2) | ||
| Fat tissues | - | - | - | - | - | - | - | - | - | - | 2 (0.4) | 6 (1.4) | ||
| Seminal vesicle | - | - | - | - | - | - | - | - | - | 1 (0.2) | 4 (1) | |||
| Others | 4 (4) | 5 (11) | - | - | 18 (31) | 52 (30.6) | - | - | - | - | ||||
| BCR-free rate | - | - | ||||||||||||
| 1y | - | - | - | - | - | - | 89 | 94 | ||||||
| 3y | 92.2 | 92.4 | 83.5 | 84 | 92.1 (pT2) 60.0 (pT3) |
96.8 (pT2) 67.3 (pT3) |
89.9 | 88.9 | - | - | 81 | 87 | ||
| 5y | - | - | - | - | 84.7 | 88.0 | - | - | 77 | 80 | ||||
GS Gleason score; PSM positive surgical margin; BCR biochemical recurrence